AMRN:NSD-Amarin Corporation plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.30

Change

-0.06 (-1.79)%

Market Cap

USD 1.39B

Volume

3.26M

Avg Analyst Target

USD 11.33 (+243.43%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Amarin Corporation plc (AMRN) Stock Analysis:
Based on the Amarin Corporation plc stock forecasts from 2 analysts, the average analyst target price for Amarin Corporation plc is USD 11.33 over the next 12 months. Amarin Corporation plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amarin Corporation plc is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Amarin Corporation plc’s stock price was USD 3.30. Amarin Corporation plc’s stock price has changed by -0.11% over the past week, -0.17% over the past month and -46.77% over the last year.

About

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to ...Read More

Company Website : https://www.amarincorp.com

Address : Grand Canal Docklands, Dublin, Ireland, 2

Employees : 1,000

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.14

52 Week High : 9.25

Short Ratio : 3.77

52 Week Low : 3.11

Shorted Shares : 14,293,703

200 Day Moving Average : 4.57

Shorted Shares Previous Month : 17,708,472

50 Day Moving Average : 3.60

Shares Held By Insiders : 1.24%

Short Percentage : 4.76%

Shares Held by Institutions : 31.53%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

 USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

 USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

 USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

 USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

 USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

 USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

 USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

 USD17.76B N/A N/A

ETFs Containing AMRN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.08% 83% B 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.08% 83% B 57% F
Trailing 12 Months  
Capital Gain -46.77% 56% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.77% 56% F 24% F
Trailing 5 Years  
Capital Gain 11.86% 62% D- 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.86% 62% D- 37% F
Average Annual (5 Year Horizon)  
Capital Gain 93.54% 87% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.54% 87% B+ 93% A
Risk Return Profile  
Volatility (Standard Deviation) 215.75% 12% F 6% F
Risk Adjusted Return 43.35% 74% C 62% D-
Market Capitalization 1.39B 84% B 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1,675.00 2% F 1% F
Price/Book Ratio 2.08 66% D 55% F
Price / Cash Flow Ratio -64.07 95% A 90% A-
EV/EBITDA 151.52 4% F 6% F
Management Effectiveness  
Return on Equity -0.33% 92% A- 51% F
Return on Invested Capital -3.17% 82% B- 40% F
Return on Assets 0.98% 93% A 52% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.77 45% F 31% F
Short Percent 4.76% 46% F 34% F
Beta 2.14 11% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.